In contrast, a pooled post-hoc analysis of five clinical trials for children and young adults treated with CD19 CAR T cells for ALL at the Children's Hospital of Philadelphia recently analyzed patients who had a history of CNS involvement within the 12 months prior to CAR T-cell infusion. The gene discussed is CD19; the disease is acute lymphoblastic leukemia.